missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human CASC4 (aa 151-229) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (82%), Rat (82%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-60201 (PA5-60201. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The increased expression level of this gene is associated with HER-2/neu proto-oncogene overexpression. Amplification and resulting overexpression of this proto-oncogene are found in approximately 30% of human breast and 20% of human ovarian cancers. Further characterization of the product of this gene may yield insight into the fundamental biology and pathogenetic effects of HER-2/neu overexpression in human breast and ovarian cancer cells. Alternatively spliced variants encoding different isoforms have been identified for this gene.
Specifications
Specifications
| Accession Number | Q6P4E1 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 113201 |
| Name | Human CASC4 (aa 151-229) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | cancer susceptibility candidate 4; cancer susceptibility candidate gene 4 protein; Cancer susceptibility candidate gene 4 protein homolog; Casc4; D130060C09Rik; gene associated with HER-2/neu overexpression; H63; Protein CASC4; UNQ2573/PRO6308; VGFG2573 |
| Common Name | CASC4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction